Patent granted to Mogen Int. (now Syngenta Mogen B.V.)
The United States patent granted to Syngenta Mogen B.V., is directed to the use of a Cre (c ausing recombination)-recombinase capable of causing site-specific recombination of two separated DNA molecules present in the same Agrobacterium strain. The resulting plasmid is a co-integrated plasmid having a gene of interest and is useful for plant transformation.
The related European patent is similar to the United States patent as both disclose a site-specific recombination system for the generation of a site-specific co-integrated plasmid for plant transformation. In the European patent, however, the recombinase is not limited to Cre recombinase.
Specific Patent Information
|Patent Number||Title, Independent Claims and Summary of Claims||Assignee|
||Title – Agrobacterium bacteria capable of site-specific recombination
The patent discloses that a first plasmid bearing a recombination site combines, in a site-specific fashion, with a second plasmid also bearing a recombination site to generate a site-specific co-integrated plasmid. The second plasmid contains a gene of interest linked to a right T-border. The production of the co-integrated plasmid does not require homologous recombination. The Agrobacterium strains used for plant transformation contain the site-specific co-integrated plasmid with the exogenous DNA to plants.
The patent claims an Agrobacterium strain with
The claim is a bit ambigious in that it doesn’t state that the recombination site is necessarily recognized by the Cre recombinase, though the specification discloses that an exemplary site is a loxP seqence.
Syngenta Mogen B.V.
|EP 628082 B1
||Title – Agrobacterium strains capable of site-specific recombination
Designated contracting States at the time of grant are: Austria (patent lapsed as reported by INPADOC), Belgium, Switzerland, Germany, Denmark (patent lapsed as reported by INPADOC), Spain, France, United Kingdom, Greece, Ireland (patent lapsed as reported by INPADOC), Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Portugal, Sweden (patent lapsed as reported by INPADOC).
Both of Syngenta Mogen’s patents in the United States and in Europe encompass Agrobacterium strains having a plasmid with a gene encoding a recombinase, a sequence to control its expression, vir functions, and a first recombination site.
Unlike the United States patent, the claims of the European patent are broader as the recombinase is not limited to a Cre recombinase. Other site-specific recombinases may be encompassed by the European patent claims. The European patent does explicitly claim that the recombinase can mediate recombination between the first recombination site and a second recombination site but claim 1 does not require that the first or second site be on a plasmid.
Note: Patent information on this page was last updated on 1 March 2006.